The benefits of Novartis’ new anti-inflammatory treatment outweigh its risks, according to FDA reviewers, an opinion that improves the odds of approval for a drug the company hopes can bring in blockbuster sales.

…read more

Source: Novartis’ psoriasis drug looks good enough to approve, FDA staff says


0 No comments